Every Form 4 that Teladoc Health, Inc. (TDOC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TDOC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TDOC filings page.
Teladoc Health, Inc. (TDOC) reported that Chief Executive Officer and director Charles Divita III exercised equity awards and sold shares. On September 10, 2026, performance stock units for 3,642 shares and restricted stock units for 39,160 shares converted on a one-for-one basis into common stock. On September 11, 2026, he sold 17,805 common shares at $6.104 per share, with the filing stating the sale was to cover tax withholding obligations related to these vestings.
Teladoc Health, Inc. (TDOC) reported that Carlos Nueno, President, International, had restricted stock units convert into a total of 13,273 shares of common stock on September 1, 2026, on a one-for-one basis. On September 2, 2026, he sold 6,200 shares at $6.301 per share, and a footnote states these shares were sold to cover the tax withholding obligation arising from the RSU vesting. No Rule 10b5-1 trading plan is reported.
Teladoc Health, Inc. (TDOC) reported insider equity activity by Chief Legal Officer and Secretary Adam C. Vandervoort. On September 1, 2026, his restricted stock units and performance stock units were converted into an aggregate of 14,928 shares of common stock on a one-for-one basis as vesting occurred. On September 2, 2026, he sold 7,573 shares of common stock at $6.301 per share, and a footnote states these shares were sold to cover the tax withholding obligation arising from the vesting of these awards. No Rule 10b5-1 trading plan is reported.
Teladoc Health, Inc. (TDOC) officer Kelly Bliss, President, U.S. Group Health, reported vesting and settlement of equity awards and a related sale. On September 1, 2026, she converted 15,311 restricted and performance stock units into the same number of Teladoc common shares. On September 2, 2026, she sold 7,357 common shares at $6.301 per share, with the company stating the sale was to cover tax withholding obligations arising from the vesting of her stock unit awards. Following these transactions, she continues to hold 7,798 performance stock units directly.
Teladoc Health, Inc. (TDOC) reports that Chief Accounting Officer Joseph Ronald Catapano settled equity awards and a related tax sale. On September 1, 2026, he converted 833 restricted stock units and 39 performance stock units into the same number of TDOC common shares on a one-for-one basis. On September 2, 2026, he sold 274 common shares at $6.301 per share, with the company stating this sale was to cover the tax withholding obligation arising from the vesting of these awards. Following the September 1 transactions, 5,001 restricted stock units and 232 performance stock units remained outstanding. No Rule 10b5-1 trading plan is indicated.
Teladoc Health, Inc. (TDOC) reported that Chief Executive Officer and director Charles DiVita III had restricted and performance stock units vest into common stock and sold a portion of shares. On September 1, 2026, 42,277 restricted stock units and 1,966 performance stock units converted one-for-one into common shares. On September 2, 2026, 18,327 common shares were sold at $6.30 per share to cover tax withholding obligations related to these vestings. No Rule 10b5-1 trading plan is reported for these transactions.
Teladoc Health, Inc. (TDOC) reports that Fernando M. Rodrigues, President of BetterHelp, converted a total of 15,251 restricted stock units into an equal number of common shares on September 1, 2026, then sold 15,251 common shares on September 2–3, 2026. One sale covered tax withholding on RSU vesting and another was executed under a Rule 10b5-1 trading plan adopted on November 3, 2025.
Teladoc Health, Inc. (symbol: TDOC) is the issuer of record for a Form 4 filing submitted to the SEC.
Anquillare Mark V reported acquisition or exercise transactions in this Form 4 filing.
Teladoc Health, Inc. reported that director Mark V. Anquillare received a grant of 37,425 Restricted Stock Units on 2026-08-03, each representing a contingent right to one share of common stock. One-third of the units vest on the first anniversary of the grant, with the remainder vesting in eight substantially equal quarterly installments, leaving him with 37,425 RSUs directly held after the award.
Teladoc Health, Inc. executive Kelly Bliss, President of U.S. Group Health, sold 2,500 shares of Teladoc common stock in an open-market transaction at $9.50 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025. After this sale, she directly holds 84,878 Teladoc shares.
Teladoc Health, Inc. Chief Accounting Officer Joseph Ronald Catapano reported the vesting of restricted stock units and a related share sale. On July 1, 2026, 2,083 restricted stock units converted into the same number of common shares at a conversion price of $0.00 per share. According to the footnotes, these units convert to Teladoc common stock on a one-for-one basis and relate to a 25,000-unit grant awarded on October 1, 2024.
On July 2, 2026, 653 common shares were sold at $9.10 per share. A footnote explains that these shares were sold to cover the tax withholding obligation arising from the RSU vesting, indicating a compensation-related, non-discretionary sale rather than an ordinary portfolio transaction. Following these transactions, Catapano directly holds 12,267 Teladoc common shares, and 10,418 restricted stock units remain outstanding.
Teladoc Health, Inc. executive Kelly Bliss, President, U.S. Group Health, sold 2,500 shares of common stock in an open-market transaction at $9.00 per share, totaling $22,500. After the sale, she directly holds 87,378 shares. The transaction was executed under a Rule 10b5-1 trading plan adopted on August 14, 2025.
Teladoc Health, Inc. executive Kelly Bliss, President, U.S. Group Health, reported an open-market sale of common stock. On June 29, 2026, she sold 2,500 shares of Teladoc Health common stock at $8.50 per share.
The filing states that this transaction was executed under a Rule 10b5-1 trading plan adopted on August 14, 2025, indicating it was pre-arranged rather than timed discretionarily. After this sale, Bliss directly holds 89,878 shares of Teladoc Health common stock.
Teladoc Health, Inc. CEO Charles DiVita III reported a mix of equity compensation activity and related share sales. On June 10, 2026, he exercised restricted stock units and performance stock units that convert one-for-one into common shares, receiving 39,160 and 3,642 shares of common stock, respectively.
On June 11, 2026, he sold 18,074 shares of common stock at $6.942 per share. A footnote states these shares were sold to cover the tax withholding obligation from the vesting of his performance and restricted stock unit awards, rather than as a discretionary open-market sale for liquidity.
After these transactions, DiVita directly holds 414,622 shares of Teladoc common stock. Footnotes also note he earned 23,591 performance stock units on June 10, 2026, scheduled to vest partially on March 10, 2026 with the remainder in five quarterly installments, and that a prior grant of 469,924 restricted stock units from June 10, 2024 continues to vest over time.
Teladoc Health, Inc. executive Fernando M. Rodrigues, President of BetterHelp, reported an open-market sale of 9,572 shares of common stock at $7.40 per share. Following this transaction, his directly held common stock position in this account was reduced to 0 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 3, 2025, indicating the trades were scheduled in advance.
Teladoc Health, Inc. executive Fernando M. Rodrigues, President of BetterHelp, reported a combination of stock vesting and related share sales. On June 1, 2026, restricted stock units converted into 15,249 shares of Teladoc common stock, reflecting compensation awards that vest over time.
On June 2, 2026, Rodrigues sold 5,677 shares of common stock at an average price of $7.627 per share to cover the tax withholding obligation tied to this RSU vesting. After these transactions, he directly held 9,572 shares of Teladoc common stock, while continuing to hold additional restricted stock units that convert to common stock on a one-for-one basis as they vest.
Teladoc Health, Inc. insider Adam C. Vandervoort, the company’s Chief Legal Officer and Secretary, reported equity compensation vesting and related share sales. On June 1, 2026, restricted stock units and performance stock units converted on a one-for-one basis into a total of 14,928 shares of common stock. On June 2, 2026, he sold 7,906 shares of common stock at $7.627 per share to satisfy the tax withholding obligation tied to these vesting awards. Following these transactions, Vandervoort directly owned 110,261 shares of Teladoc common stock.
Teladoc Health, Inc. reported that Carlos Nueno, its President, International, exercised restricted stock units and sold shares primarily to cover taxes. On June 1, 2026, he converted a total of 13,272 restricted stock units into the same number of Teladoc common shares at a conversion price of $0.00 per share, with the units converting on a one-for-one basis into common stock.
On June 2, 2026, Nueno sold 6,196 shares of common stock at an average price of $7.627 per share. A footnote explains these shares were sold to cover the tax withholding obligation related to the vesting of his restricted stock unit awards, indicating a tax-driven disposition rather than a discretionary open-market sale. After these transactions, he directly held 57,671 shares of Teladoc common stock and 13,670 restricted stock units.
The filing also notes earlier equity grants, including 54,675 restricted stock units granted on March 19, 2024 and 104,602 restricted stock units granted on March 1, 2025, both subject to multi-year vesting schedules. These awards illustrate that a significant portion of Nueno’s compensation remains tied to Teladoc’s future share performance through ongoing RSU vesting.
Teladoc Health, Inc. chief executive officer Charles Divita III reported compensation-related stock activity. On June 1, 2026, previously granted restricted stock units and performance stock units converted into a total of 44,242 shares of common stock on a one-for-one basis.
On June 2, 2026, he sold 19,132 shares of common stock at $7.627 per share, with the footnotes stating the shares were sold to cover tax withholding obligations tied to the vesting of these awards. After the transactions, he directly owned 389,894 common shares.
Teladoc Health Chief Accounting Officer Joseph Ronald Catapano reported routine equity compensation activity. On June 1, 2026, he exercised restricted stock units and performance stock units that converted into a total of 872 shares of common stock at $0.00 per share. On June 2, 2026, 284 shares of common stock were sold at $7.627 per share to cover tax withholding obligations related to these vestings. After these transactions, he directly holds 10,837 shares of Teladoc Health common stock.
Teladoc Health President U.S. Group Health Kelly Bliss reported routine equity compensation activity. On June 1, 2026, she exercised performance and restricted stock units that converted into a total of 15,310 shares of common stock at a conversion price of $0.00 per share.
On June 2, 2026, she sold 7,679 common shares at $7.627 per share to cover the tax withholding obligation tied to these vestings, according to the footnotes. After these transactions, she directly owned 92,378 Teladoc shares, indicating a net increase in her equity position.
Smith Mark Douglas reported acquisition or exercise transactions in this Form 4 filing.
Teladoc Health director Mark Douglas Smith received a grant of 30,441 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Teladoc common stock. The RSUs vest in full on the earlier of May 21, 2027 or the day immediately before Teladoc’s 2027 annual shareholder meeting.
Vested shares will be delivered to Smith upon the earliest of several events: within a specified period after separation of service, around the time of a qualifying Change of Control as defined in Teladoc’s Deferred Compensation Plan for Non-Employee Directors, or upon his death. This is a compensation-related equity award, not an open-market stock purchase or sale.
Paulus Kenneth H reported acquisition or exercise transactions in this Form 4 filing.
Teladoc Health, Inc. director Kenneth H. Paulus received a grant of 30,441 restricted stock units, each representing one share of Teladoc common stock. These units vest in full on the earlier of May 21, 2027 or the day before the company’s 2027 annual stockholder meeting, with delivery of vested shares tied to separation of service, a qualifying change of control, or death.
Fenwick Sandra L reported acquisition or exercise transactions in this Form 4 filing.
Teladoc Health, Inc. director Sandra L. Fenwick received a grant of 30,441 restricted stock units, each representing one share of Teladoc common stock. These RSUs vest in full on the earlier of May 21, 2027 or the day immediately before Teladoc’s 2027 annual stockholder meeting.
Vested shares will be delivered to Fenwick on the earliest of several events: within a set period after her separation of service, around a qualifying Change of Control as defined in Teladoc’s Deferred Compensation Plan for Non-Employee Directors, or upon her death.
Teladoc Health director David L. Shedlarz reported equity compensation and an award vesting event. On May 21, 2026, he received a grant of 30,441 restricted stock units (RSUs), each representing a right to one share of Teladoc common stock, vesting in full on the earlier of May 21, 2027 or the day before the 2027 annual meeting.
On May 20, 2026, he acquired 29,986 shares of common stock through an exercise or conversion of derivative securities and exercised 28,986 RSUs, fully settling that prior award. Following the stock acquisition, he directly held 61,266 common shares.
Teladoc Health director Catherine Jacobson reported routine equity compensation activity. On May 21, 2026 she received a grant of 30,441 restricted stock units, each representing one share of Teladoc common stock, vesting in full on the earlier of May 21, 2027 or the day before the 2027 annual meeting of stockholders.
On May 20, 2026 she also exercised 28,986 previously granted restricted stock units that vested in full on May 20, 2026, converting them into the same number of common shares. Following these transactions, she holds 66,853 Teladoc common shares directly and 30,441 restricted stock units.
Teladoc Health director David B. Snow, Jr. reported equity compensation-related transactions with no open-market buying or selling. He received a grant of 30,441 restricted stock units, each representing one share of Teladoc common stock, vesting in full on the earlier of May 21, 2027 or the day before the 2027 annual stockholder meeting. He also exercised 28,986 restricted stock units into an equal number of common shares, fully settling that prior RSU award. Following these transactions, he holds 113,032 shares of common stock directly and 52,000 shares indirectly through the David B. Snow, Jr. Irrevocable Trust for the benefit of his children.
Teladoc Health Chief Accounting Officer Joseph Ronald Catapano reported routine equity compensation activity and a small related share sale. On April 1, 2026, restricted stock units converted into 2,083 shares of Teladoc common stock on a one-for-one basis at a conversion price of $0.00.
On April 2, 2026, he sold 675 common shares at $5.114 per share solely to cover the tax withholding obligation tied to the RSU vesting, rather than as a discretionary open-market sale. After these transactions, he directly held 10,249 common shares.
The filing notes that on October 1, 2024, he was granted 25,000 restricted stock units, with one-third vesting on the first anniversary of the grant and the remainder vesting in eight substantially equal quarterly installments thereafter.
SALKA SUSAN R reported acquisition or exercise transactions in this Form 4 filing.
Teladoc Health, Inc. director Susan R. Salka received a grant of 48,638 restricted stock units (RSUs) linked to Teladoc common stock. Each RSU represents a contingent right to receive one share of common stock. One-third of the RSUs vest on the first anniversary of the grant date, with the remaining units vesting in eight substantially equal quarterly installments thereafter. Following this award, Salka directly holds 48,638 RSUs reported in this filing.
Teladoc Health, Inc. President, U.S. Group Health, Kelly Bliss reported compensation-related equity activity involving performance stock units tied to common stock. On 2026-02-27, she was granted 15,596 performance stock units, each representing a contingent right to receive one share of TDOC common stock.
The award size was determined using metrics based on Teladoc’s 2025 financial results, and the units vest one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments. The filing also records the exercise or conversion of 5,198 performance stock units into common stock and amends a prior Form 4 to correct the originally reported number of units awarded.
Teladoc Health, Inc. reported insider activity by CEO Charles DiVita III involving equity awards, vesting, and related tax sales. On March 10, 2026, restricted stock units and performance stock units converted one-for-one into a total of 64,653 shares of common stock. He was also awarded 43,703 performance stock units, with vesting tied to the company’s 2025 financial results and a schedule that began March 10, 2026. On March 11, 2026, 27,731 shares of common stock were sold at $5.49 per share to cover tax withholding obligations related to these vestings. After these transactions, DiVita directly owned 364,784 shares of Teladoc common stock.
Teladoc Health’s chief legal officer Adam C. Vandervoort reported a mix of equity awards, vesting and a related share sale. On March 2, he sold 27,083 shares of common stock at $5.117 per share to cover tax withholding obligations tied to recently vesting awards. Following this sale, he directly owned 103,239 common shares.
On March 1, he received a grant of 181,661 restricted stock units, each representing a contingent right to one Teladoc common share. Around February 27, multiple restricted stock unit and performance stock unit awards converted into common stock on a one-for-one basis, and he also earned 5,107 performance stock units based on metrics related to the company’s 2025 financial results.
Teladoc Health, Inc. director and CEO Charles DiVita III reported a mix of stock sales, grants, and conversions. He sold 50,145 shares of common stock at $5.117 per share in an open-market transaction, with a footnote stating the sale was to cover tax withholding obligations from vesting equity awards. After this sale, he directly held 327,862 common shares.
DiVita also acquired 692,041 restricted stock units and 23,591 performance stock units, each representing a contingent right to receive one share of Teladoc common stock on a one-for-one basis, subject to vesting schedules tied in part to 2025 financial metrics. Additional exercises and conversions of 169,107 and 7,864 derivative units into common shares were reported, reflecting ongoing equity-based compensation activity.
Teladoc Health, Inc.’s Chief Accounting Officer, Joseph Ronald Catapano, reported a mix of stock sales, vesting, and new equity awards. He sold 1,333 shares of common stock at $5.117 per share, with a footnote stating the sale was made to cover tax withholding tied to vesting of his restricted and performance stock units.
On the equity award side, he received a grant of 15,000 restricted stock units, each representing a contingent right to one share of Teladoc common stock, and 465 performance stock units earned based on 2025 financial metrics, also convertible one-for-one into common shares. Footnotes state these awards generally vest one-third on the first anniversary of the grant or earning date, with the remainder vesting in eight substantially equal quarterly installments thereafter. Following these transactions, he directly owned 8,841 shares of common stock, plus outstanding RSU and PSU awards.
Teladoc Health, Inc. executive Kelly Bliss, President of U.S. Group Health, reported a mix of stock sales and equity awards. Bliss sold 26,647 shares of common stock in an open-market transaction at $5.117 per share to cover tax withholding obligations related to vesting equity awards, and held 84,747 common shares afterward.
On March 1, 2026, Bliss received a grant of 181,661 restricted stock units, each representing a contingent right to one Teladoc share, generally vesting one-third on the first anniversary of the grant date with the balance in eight quarterly installments. Around February 27, 2026, multiple restricted stock unit and performance stock unit awards were exercised or earned, including 27,458 performance stock units determined using metrics tied to Teladoc’s 2025 financial results, all converting to common stock on a one-for-one basis.
Teladoc Health, Inc. executive Fernando M. Rodrigues, President of BetterHelp, reported multiple stock transactions involving common shares and restricted stock units. He sold 16,314 common shares at $5.117 per share and 25,086 shares at $4.982 per share, totaling 41,400 shares sold.
Footnotes state these shares were sold to cover tax withholding obligations tied to vesting of restricted stock units and were executed under a Rule 10b5-1 trading plan adopted on November 3, 2025. Rodrigues also reported grants and exercises of restricted stock units, including 181,661 units granted on March 1, 2026, which each represent a contingent right to receive one share of Teladoc common stock and vest over time in scheduled installments.
Teladoc Health executive Carlos Nueno reported multiple equity transactions involving Teladoc Health, Inc. common stock and equity awards. On March 2, 2026, he sold 20,165 shares of common stock in an open‑market transaction at $5.117 per share, with a footnote stating the sale was to cover tax withholding obligations from vesting awards.
On March 1, 2026, he received a grant of 173,010 restricted stock units with each unit representing a contingent right to one Teladoc share. On February 27, 2026, several blocks of restricted stock units and performance stock units converted into common stock on a one‑for‑one basis, increasing his shareholdings. After these transactions, he directly owned 50,595 common shares.
Smith Michael S reported acquisition or exercise transactions in this Form 4 filing.
Teladoc Health, Inc. director Michael S. Smith received a grant of 53,648 restricted stock units, each representing the right to receive one share of TDOC common stock. One-third of these units vest on the first anniversary of the grant date, with the remaining units vesting in eight substantially equal quarterly installments thereafter.
Teladoc Health’s Chief Accounting Officer reported routine equity transactions in company stock. On 01/02/2026, restricted stock units converted into 2,083 shares of Teladoc Health common stock on a one-for-one basis. On 01/05/2026, the officer sold 758 shares at $7.145 per share to cover tax withholding obligations related to the vesting of restricted stock units.
After these transactions, the officer held 6,686 shares of Teladoc Health common stock directly and 14,584 restricted stock units. The filing notes that an earlier grant of 25,000 restricted stock units from October 1, 2024 vests one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter.
Teladoc Health director reports RSU conversion into common stock. On 12/19/2025, the reporting person converted 1,016 restricted stock units into an equal number of Teladoc Health common shares, increasing directly held common stock to 9,145 shares. A related derivative line shows 1,016 restricted stock units being settled for 1,016 common shares at an exercise price of $0, leaving 3,050 restricted stock units beneficially owned.
The filing notes that these restricted stock units were originally granted on September 20, 2023, in an award of 12,195 units that vest one‑third on the first anniversary of the grant date, with the remaining units vesting in eight substantially equal quarterly installments thereafter.
Teladoc Health’s chief executive officer reported new stock activity in a Form 4 filing. On December 10, 2025, 39,160 restricted stock units vested and converted into the same number of shares of Teladoc common stock. On December 11, 2025, the CEO sold 17,138 shares of common stock at an average price of $7.6343 per share to cover tax withholding obligations tied to this vesting.
After these transactions, the CEO directly owned 201,036 shares of Teladoc common stock and held 234,963 restricted stock units. The restricted stock units referenced stem from a grant of 469,924 units made on June 10, 2024, which vests one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments.
Teladoc Health, Inc. insider equity activity: A company officer, the President of BetterHelp, reported multiple stock transactions in early December 2025. On December 1, 2025, the officer exercised restricted stock units that converted on a one-for-one basis into 5,491 shares of Teladoc common stock and an additional 1,042 shares, both at an exercise price of $0, reflecting vesting of prior equity awards.
On December 2, 2025, the officer sold 2,324 shares of common stock at $7.488 per share to cover tax withholding obligations related to the vesting. On December 3, 2025, a further 4,209 shares were sold at $7.48 per share pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2024 and amended on November 27, 2024. Following these transactions, the form shows remaining holdings in restricted stock units, including 21,966 and 5,210 units from prior grants that continue to vest over time.
Teladoc Health’s chief legal officer and secretary reported routine stock activity related to vesting of prior equity awards. On December 1, 2025, 1,505 performance stock units and two blocks of restricted stock units (4,418 and 5,350 units) converted on a one-for-one basis into shares of Teladoc common stock. On December 2, 2025, 5,720 common shares were sold at $7.488 per share to satisfy tax withholding obligations tied to these vesting events. After these transactions, the officer directly owns 80,732 shares of common stock and continues to hold derivative awards, including performance and restricted stock units scheduled to vest over time.
Teladoc Health insider equity activity: A Teladoc Health officer, identified as President, International, reported routine equity compensation transactions involving company common stock. On December 1, 2025, the officer acquired 1,056 shares of Teladoc common stock through performance stock units converting on a one-for-one basis and an additional 3,101 shares and 4,556 shares through restricted stock units that also convert one-for-one into common stock. These awards stem from prior grants made in March 2023 and March 2024 with scheduled vesting over time.
On December 2, 2025, the officer sold 3,897 shares of Teladoc common stock at a price of $7.488 per share to cover tax withholding obligations related to the vesting of the performance and restricted stock units. Following these transactions, the officer continued to hold tens of thousands of Teladoc shares directly, reflecting ongoing equity ownership linked to prior stock unit grants.
Teladoc Health, Inc. officer reports stock unit vesting and tax-sale transaction. A Teladoc Health executive, serving as President, U.S. Group Health, reported the conversion of performance stock units and restricted stock units into common stock and a related sale of shares.
On 12/01/2025, 1,189 performance stock units and two blocks of restricted stock units totaling 8,346 units (3,488 and 4,858) converted into the same number of Teladoc common shares on a one-for-one basis. On 12/02/2025, 4,582 shares of common stock were sold at $7.488 per share to cover tax withholding obligations from these vestings.
After these transactions, the reporting person beneficially owned 60,054 shares of Teladoc common stock directly, along with remaining derivative holdings that include performance and restricted stock units scheduled to vest over time under prior grants.
Teladoc Health, Inc. director reports open-market stock purchase
A Teladoc Health, Inc. director filed a Form 4 reporting the purchase of 10,000 shares of the company’s common stock. The transaction took place on 11/14/2025 at a price of $6.94 per share, resulting in beneficial ownership of 10,000 shares following the trade, held directly.
The filing notes that this transaction was carried out under a Rule 10b5-1 trading plan that the reporting person adopted on August 15, 2025. Rule 10b5-1 plans are pre-arranged trading programs intended to allow insiders to buy or sell shares according to preset instructions.
Joseph Ronald Catapano, Chief Accounting Officer of Teladoc Health, Inc. (TDOC), reported the vesting and partial sale of restricted stock units. On 10/01/2025 8,333 restricted stock units converted to 8,333 shares of common stock. On 10/02/2025 he sold 2,972 shares at $7.885 per share to cover tax withholding, leaving 5,361 shares beneficially owned following the sale. The filing notes the RSU grant of 25,000 units on 10/01/2024 with one-third vesting on the first anniversary and the remainder vesting in eight substantially equal quarterly installments.